Welcome to our dedicated page for Zimmer Biomet SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zimmer Biomet’s filings rarely read like light literature—hundreds of pages detail knee, hip, and S.E.T. sales, FDA clearances, and the cost of bringing robotic surgery to market. Sorting through that volume to spot revenue shifts or a device-recall risk is a real challenge.
Stock Titan solves that problem. Our AI turns dense disclosures into plain language so you can understand Zimmer Biomet SEC documents with AI in minutes, not hours. Need to track Zimmer Biomet insider trading Form 4 transactions? We stream Form 4 insider transactions in real-time and flag unusual executive stock moves. Trying to compare margins across segments? The quarterly earnings report 10-Q filing is summarised automatically, while key trends are highlighted for fast Zimmer Biomet earnings report filing analysis.
You’ll find every form the moment it hits EDGAR—10-K annual report simplified, 8-K material events explained, proxy statement executive compensation breakdowns, and each Zimmer Biomet 8-K material events explained for device launches or recalls. Our platform layers AI-powered summaries, searchable text, and red-line comparisons so you can:
- Monitor Zimmer Biomet executive stock transactions Form 4 before material events
- Follow segment-level revenue trends across knees, hips, and robotics
- Review risk-factor changes without rereading 300 pages
Whether you’re an analyst asking “Where can I find Zimmer Biomet’s quarterly earnings report 10-Q filing?” or a surgeon-investor wondering “How to read Zimmer Biomet’s 10-K annual report”, our exhaustive library keeps you current with real-time updates and expert context. Complex orthopedic disclosures, explained simply.
Schedule 13G/A summary: Dodge & Cox reports beneficial ownership of 22,097,463 shares of Zimmer Biomet common stock, representing 11.2% of the class. The firm reports sole voting power over 20,878,838 shares and sole dispositive power over 22,097,463 shares, with no shared voting or dispositive power. The filing identifies Dodge & Cox as an investment adviser and states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control. The Dodge & Cox Stock Fund is disclosed as holding 14,622,400 shares (7.4%).
Kevin R. Thornal, Group President-Global Business at Zimmer Biomet (ZBH), was granted 29,870 restricted stock units (RSUs) on 08/01/2025. Each RSU represents a contingent right to one share of common stock and the award carries a $0 purchase price, indicating a compensation grant rather than a market purchase. The RSUs vest in three equal installments, with one-third vesting on each of August 1, 2026, August 1, 2027 and August 1, 2028. Following the reported transaction, Mr. Thornal beneficially owns 29,870 shares directly. This filing discloses a routine executive equity award intended to align the officer’s incentives with shareholder value over a multi-year period.
Zimmer Biomet reports a proposed sale of 7,500 common shares through Fidelity Brokerage on the NYSE, with an aggregate market value of $766,708.20, scheduled for 08/13/2025. The filing lists 198,095,984 shares outstanding and shows the securities to be sold were acquired through employee programs: small ESPP purchases on 12/29/2023 (25), 06/28/2024 (28) and 12/31/2024 (29), and restricted stock vesting on 02/18/2025 (5,911) and 02/20/2025 (1,507). The filer reports Nothing to Report for sales in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) filed an 8-K dated 7 Aug 2025 to disclose Item 2.02 – Results of Operations and Financial Condition.
- The company issued a press release (Exhibit 99.1) announcing its financial results for the quarter ended 30 Jun 2025; the actual figures are not included in the filing.
- The 8-K clarifies that the press release is being furnished, not filed, thereby limiting Exchange Act liability.
- No other material transactions, guidance changes or strategic updates are reported.
The document also lists ZBH’s registered securities (common stock and three note issues) and provides standard emerging-growth-company and signature boilerplate.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) has entered into a definitive Agreement and Plan of Merger to acquire Monogram Technologies Inc. On 11 July 2025 the company and its wholly-owned subsidiary, Honey Badger Merger Sub, signed the merger agreement under which Merger Sub will be merged into Monogram, making Monogram a wholly-owned subsidiary of Zimmer Biomet at closing.
Transaction consideration will be paid entirely in cash plus a contractual contingent value right (CVR):
- Monogram common stockholders will receive $4.04 per share in cash plus one CVR.
- Series D preferred holders will receive $2.25 per share in cash plus any accrued but unpaid dividends.
- Series E preferred holders will receive $100.00 per share in cash.
The company furnished an investor presentation (Exhibit 99.1) and a joint press release (Exhibit 99.2); both are incorporated by reference but are deemed “furnished,” not “filed,” under the Exchange Act. Zimmer Biomet stresses that forward-looking statements in the materials are subject to numerous risks, including regulatory approvals, Monogram shareholder approval, competing offers, integration challenges, and potential termination fees.
No financial statements or pro-forma financial data were included in this Form 8-K. Closing timing and expected financial impact were not disclosed.
FAQ
What is the current stock price of Zimmer Biomet (ZBH)?
What is the market cap of Zimmer Biomet (ZBH)?
